arrow
P

Petr Hrúz

Medical University of Vienna
H指数:37
被引数:5,032

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Wide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impaction

最佳实践建议与疑似嗜酸性食管炎相关食物嵌塞的实际管理之间存在巨大差异

2025-10-010
PRE
Blood-borne immune cells carry low biomass DNA remnants of microbes in patients with colorectal cancer or inflammatory bowel disease

血液携带的免疫细胞在结直肠癌或炎症性肠病患者中携带低生物量的微生物DNA残留

2025-07-200
OAAI
Usefulness of the Screening Tool for AdheRence to medicineS (15-STARS) in clinical practice: Subset-analysis of a multicentric study with inflammatory bowel disease (IBD) patients

药物依从性筛查工具(15-STARS)在临床实践中的实用性:一项针对炎症性肠病(IBD)患者的多中心研究的子集分析

2025-06-030
PRE
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: An Open-Label Extension Study

Biedermann, L.; Schlag, C.; Straumann, A.; Lucendo, A.J.; Miehlke, S.; Vieth, M.; Santander, C.; Ciriza de Los Rios, C.; Schmöcker, C.; Madisch, A.; et al. 布地奈德口腔崩解片治疗嗜酸性食管炎的疗效与安全性:最长3年随访结果——一项开放标签扩展研究。Clin. Gastroenterol. Hepatol. 2024; 已接收. [Google Scholar] [CrossRef] [PubMed]

2024-12-160
OAAI
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial

富含花青素的提取物治疗溃疡性结肠炎的疗效和安全性: 一项随机对照试验

2024-12-040
OAAI
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey

医生和患者感知到的炎症性肠病中的粪便急迫性和失禁: 瑞士粪便急迫性调查的结果

2024-09-082
OAAI
Post-transplant Inflammatory Bowel Disease Associated with Donor-Derived TIM-3 Deficiency
2024-02-162
OAAI
AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells
2023-01-019
OAAI
Targeting colonic macrophages improves glycemic control in high-fat diet-induced obesity
2022-04-1920
OAAI
Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme
2022-04-1219
OA
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis
2020-11-01120
OAAI